BIOSYENT INC. Aktie Logo
CA0906901081
A1J6DY

BIOSYENT INC. Aktie

Kurser indlæses...

Prognose

Vi har ingen analytikerdata for denne virksomhed.

Diskussioner i communityet

Der er endnu ingen diskussion om dette aktiv.

Start diskussion

  • BioSyent records 27% revenue growth in Q1 2026 thanks to Oral Science acquisition

    BioSyent reported consolidated revenue of CAD 13.9 million for Q1 2026 (+27% year‑on‑year) and unchanged earnings per share of CAD 0.20. The acquisition of Oral Science contributed about CAD 3.0 million to March 2026 revenue; EBITDA rose to CAD 3.6 million and net income to CAD 2.345 million. The company reaffirmed its guidance (Q2 EPS CAD 0.21, Q3 EPS CAD 0.22), plans international expansion of the Oral Science product line, and warned of ongoing risks such as geopolitical tensions and rising energy costs. » Mere på de.investing.com


  • BioSyent misses revenue guidance for Q4 2025, EPS meets expectations

    BioSyent reports Q4 2025 earnings per share of CAD 0.17, in line with expectations, while revenue of CAD 9.67 million missed the CAD 10.4 million forecast by 7.02%. The company reported its 62nd consecutive profitable quarter and revenue growth of 10% year over year, supported by acquisitions such as Tibelia and strong international pharmaceutical growth. BioSyent raised the quarterly dividend for 2026 by 10% and signaled continued earnings growth through EPS guidance for 2026; the stock rose slightly in after-hours trading. » Mere på de.investing.com


  • BioSyent doubles in size through acquisition of Oral Science despite missing Q4 revenue guidance

    BioSyent reports Q4 2025 revenue of CAD 9.7m, missing analyst expectations of CAD 10.4m, but remains profitable with rising EBITDA and net income. The company completed the CAD 25.5m acquisition of Oral Science; Oral Science contributed about CAD 30.9m in revenue in 2025, which pro forma doubles the company’s size. The acquisition will be operated as a standalone oral health division, financed with cash, debt and equity, and BioSyent plans to fully repay the acquisition debt in 2026. Management highlights diversification, cross‑selling potential, a dividend increase and ongoing share buybacks, but notes integration risks and geopolitical headwinds. » Mere på de.investing.com


  • BioSyent Q3 2025: revenue rises 28%, stock slips slightly

    BioSyent reported Q3 2025 revenue of CAD 12m (+28% year‑over‑year) and net income of CAD 2.7m (+16%); EBITDA increased to CAD 3.6m with a margin of 30%. The company recorded its 61st consecutive profitable quarter and sees itself as a market leader particularly in the iron‑supplements segment. The stock fell slightly in after‑hours trading, down 0.28% to CAD 10.72. BioSyent expects last‑twelve‑months revenue to exceed CAD 42m by year‑end, holds a cash position of CAD 27.5–29m, is evaluating in‑licensing and M&A opportunities, and plans a new endocrinology product for Q1 2027. » Mere på de.investing.com


  • Biosyent Inc. posts strong Q2 growth in revenue and profit

    Biosyent Inc. reports Q2 2025 revenue up 14% to USD 10 million and net profit after taxes rising 28% to USD 2 million; EBITDA was USD 2.8 million. The acquisition of Tibeliya Global added USD 1.3 million in revenue; Feramax 45 remains a growth driver and a new Feramax product is planned for 2026. The stock rose modestly after-hours by 0.78%. Management and strategy focus on reinvesting profits into growth, a premium pricing strategy and self-pay patients, while competition, regulation and supply chains are cited as risks. » Mere på de.investing.com

I 2026 har BIOSYENT INC. Aktie allerede udloddet 0,10 € i udbytte. Den seneste udlodning fandt sted i september.

Virksomhedstal

I det seneste kvartal havde BIOSYENT INC. Aktie en omsætning på 12,26 mio. € og et nettoresultat på 1,76 mio. €
(EUR) juni 2026
YoY
Omsætning 12,26 mio. 93,17 %
Bruttofortjeneste 7,97 mio. 61,57 %
Nettoresultat 1,76 mio. 39,70 %
EBITDA 3,07 mio. 65,82 %

Fundamentale data

Nøgletal Værdi
Markedsværdi
128,19 mio. €
Antal aktier
11,31 mio.
Højeste/laveste i 52 uger
11,54 € - 6,95 €
Udbytteafkast
1,18 %
Udbytte TTM
0,13 €
Beta
0,63
P/E (PE Ratio)
20,22
PEG (PEG Ratio)
0,98
K/I (PB Ratio)
4,42
P/S (PS Ratio)
3,61

Virksomhedsprofil

BioSyent Inc. er et specialiseret farmaceutisk selskab, der indkøber, erhverver eller opnår licens til, udvikler og sælger farmaceutiske og andre sundhedsprodukter i Canada og internationalt. Selskabets produkter omfatter FeraMAX 150, et oralt hæmatinikum; FeraMAX Powder, et vandopløseligt oralt jerntilskud, som hjælper kroppen med at danne røde blodlegemer; og FeraMAX Pd Therapeutic 150 til forebyggelse og behandling af jernmangelanæmi. Selskabet tilbyder desuden Cathejell, et produkt, der er indiceret til overfladebedøvelse og smøring under forskellige procedurer, herunder cystoskopi, kateterisering, endouretral operation, endoskopi, proktoskopi, rektoskopi og trakealintubation, samt til symptomatisk behandling af smerter i forbindelse med cystitis og uretritis; RepaGyn, et vaginalt suppositorium til heling af vaginal slimhinde samt til behandling af vaginal tørhed forårsaget af overgangsalder, stress og kemoterapi; og Proktis-M, et rektalt suppositorium til heling af anus og endetarm. Derudover leverer selskabet Combogesic til moderate akutte smerter og feberreduktion hos voksne; Protect-It, et ikke-kemisk, fødevaresikkert insekticid til korn, der anvendes som forebyggende behandling mod insektangreb i opbevaret korn; og Tibella, en hormonbehandling til behandling af vasomotoriske symptomer på grund af østrogenmangel. Selskabet sælger sine produkter gennem grossister og detailkæder med apoteker. Selskabet var tidligere kendt som Hedley Technologies Inc. og ændrede navn til BioSyent Inc. i juni 2006 for at afspejle sit fremadrettede fokus på farmaceutisk marked. BioSyent Inc. blev stiftet i 2006 og har hovedkontor i Mississauga, Canada.

Navn
BIOSYENT INC. Aktie
CEO
René C. Goehrum
Hjemsted Mississauga, on
Canada
Websted
Børsnotering
08.05.1996
Medarbejdere 711
🍪

Parqet  bruger cookies. Læs mere